Abivax Statement on Short Seller Report
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abivax (ABVX) plans to file a U.S. New Drug Application for obefazimod by the end of 2026.
The company expects data from its Phase 3 ABTECT trials to support the filing with the U.S. Food and Drug Administration. Obefazimod, also known as ABX464, is in Phase 3 development for moderately to severely active ulcerative colitis.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.U.S. New Drug Application for obefazimod planned by the end of 2026, supported by Phase 3 ABTECT data
Negative
- None.
Key Figures
- U.S. FDA NDA filing
- by the end of the year
- Abivax says Phase 3 ABTECT results will support the filing
Historical Context
-
FDA feedback aligned with planned obefazimod NDA strategy and end-of-year submission target.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nda regulatory
phase 3 medical
ulcerative colitis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Abivax Statement on Short Seller Report
PARIS, France – November 20, 2026 – 10:30 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax,” the “Company,” “we” or “our”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026.
We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax’s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself. We firmly stand behind the integrity of our clinical development program, including the results of our Phase 3 ABTECT trials and the strength of the clinical data generated to date, which will support Abivax’s U.S. FDA NDA filing by the end of the year.
Notably, Scorpion Capital explicitly disclosed its short position in Abivax and its intention to begin covering a substantial portion of that position upon publication of its report, underscoring its direct financial interest in a decline in our share price. These direct financial incentives provide important context for evaluating the report.
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878
Media Contacts:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com
Longacre Square Partners
Abivax@longacresquare.com
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.